Syros Pharmaceuticals Inc

NASDAQ:SYRSUnited States

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).

Contact Information

Headquarters

35 Cambridge Park DriveCAMBRIDGE, MA, United States 02140

Phone

617-744-1340

Fax

617-744-1377

Executives

Independent Chairman of the Board

Peter Wirth

President, Chief Executive Officer, Director

Conley Chee

Chief Financial Officer

Jason Haas

President, Chief Executive Officer, Director

Gerald Quirk

Chief Medical Officer

David Roth